Novartis Japan unit charged over research manipulation

Japanese prosecutors Tuesday laid charges against the local unit of Swiss pharmaceutical giant Novartis in a widening scandal over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure drug.

Prosecutors also indicted former employee Nobuo Shirahashi, 63, alleging he manipulated the data in clinical studies that were later used in marketing the drug Valsartan.

The dual charges laid by the Tokyo District Public Prosecutor's Office—which allege that Novartis bore responsibility for Shirahashi's actions—came several weeks after he was first arrested and authorities raided the offices of Novartis Pharma KK in the Japanese capital.

The drug studies suggested Valsartan—sold under the brand name Diovan in Japan, and licensed for use in more than 100 countries—could help prevent strokes and angina, in addition to its acknowledged benefits in combating .

The firm used data from those studies to market its , playing up its supposed additional benefits.

"We take the arrest of our former employee and the indictment of our company very seriously," the unit said in a statement on its website.

"We deeply apologise to patients, their families and medical workers as well as Japanese people for causing these concerns and trouble," it added.

The 's Japan unit has also been embroiled in another scandal over allegations it did not properly disclose the possible side effects of leukaemia treatments.

In April, Novartis replaced the top executives at its Japanese arm over those allegations.

Under the country's pharmaceutical law, anyone found guilty of exaggerating advertising can face up to two years in prison or a fine of as much as two million yen ($19,000).

add to favorites email to friend print save as pdf

Related Stories

Japan prosecutors arrest ex-Novartis employee over data

Jun 11, 2014

Prosecutors on Wednesday arrested a former employee of the Japanese unit of Swiss pharmaceutical giant Novartis for allegedly manipulating research data to exaggerate the benefits of a popular blood-pressure drug.

Japan prosecutors raid Novartis over drug ad scandal

Feb 19, 2014

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Japan files criminal complaint against Novartis arm

Jan 09, 2014

Japan's health ministry on Thursday filed a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, the company said.

Japan to seek criminal prosecution of Novartis

Dec 18, 2013

Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.